Zhang Ying, Jia Beili, Li Jing, Xu Xiaomei
Department of Internal Medicine, Municipal Hospital, Qingdao, Shandong, People's Republic of China.
Department of Medical Oncology, Municipal Hospital, Qingdao, Shandong, People's Republic of China.
Tumori. 2020 Dec;106(6):NP36-NP40. doi: 10.1177/0300891619900673. Epub 2020 Feb 7.
An elderly patient with advanced small cell lung cancer who had a history of smoking and who had previously had tuberculosis and chronic kidney disease relapsed after classical treatment with etoposide combined with carboplatin.
The patient was given chemotherapy again, with albumin-bound paclitaxel, etoposide capsules, apatinib, and other treatment. The last medication was apatinib.
After treatment with anlotinib, the patient has survived for 15 months with good quality of life.
This is the first report on the precise efficacy of anlotinib in the treatment of advanced small cell lung cancer. Anlotinib is an important option for patients with small cell lung cancer.
一名老年晚期小细胞肺癌患者，有吸烟史，既往患过结核病和慢性肾脏病，在接受依托泊苷联合卡铂的经典治疗后复发。
该患者再次接受化疗，使用了白蛋白结合型紫杉醇、依托泊苷胶囊、阿帕替尼等治疗。最后使用的药物是阿帕替尼。
使用安罗替尼治疗后，患者已存活15个月，生活质量良好。
这是关于安罗替尼治疗晚期小细胞肺癌确切疗效的首篇报道。安罗替尼是小细胞肺癌患者的重要选择。
